RU2730520C2 - Твердые формы альфа, омега дизамещенного дигидроксициклопентильного соединения и способы их получения и применения - Google Patents

Твердые формы альфа, омега дизамещенного дигидроксициклопентильного соединения и способы их получения и применения Download PDF

Info

Publication number
RU2730520C2
RU2730520C2 RU2016123446A RU2016123446A RU2730520C2 RU 2730520 C2 RU2730520 C2 RU 2730520C2 RU 2016123446 A RU2016123446 A RU 2016123446A RU 2016123446 A RU2016123446 A RU 2016123446A RU 2730520 C2 RU2730520 C2 RU 2730520C2
Authority
RU
Russia
Prior art keywords
crystalline form
diluent
days
compound
crystallization time
Prior art date
Application number
RU2016123446A
Other languages
English (en)
Russian (ru)
Inventor
Ке ВУ
Гиорги АМБРУС
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Application granted granted Critical
Publication of RU2730520C2 publication Critical patent/RU2730520C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2016123446A 2013-12-13 2014-12-12 Твердые формы альфа, омега дизамещенного дигидроксициклопентильного соединения и способы их получения и применения RU2730520C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915575P 2013-12-13 2013-12-13
US61/915,575 2013-12-13
PCT/US2014/070156 WO2015089475A1 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Publications (1)

Publication Number Publication Date
RU2730520C2 true RU2730520C2 (ru) 2020-08-24

Family

ID=52282957

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016123446A RU2730520C2 (ru) 2013-12-13 2014-12-12 Твердые формы альфа, омега дизамещенного дигидроксициклопентильного соединения и способы их получения и применения

Country Status (16)

Country Link
US (2) US9353079B2 (enExample)
EP (1) EP3080096A1 (enExample)
JP (2) JP2016539994A (enExample)
KR (1) KR20160097310A (enExample)
CN (1) CN105814033B (enExample)
AU (1) AU2014361794B2 (enExample)
BR (1) BR112016013594A8 (enExample)
CA (1) CA2933556A1 (enExample)
CL (2) CL2016001448A1 (enExample)
IL (2) IL245917B (enExample)
MX (1) MX2016007717A (enExample)
RU (1) RU2730520C2 (enExample)
SA (1) SA516371307B1 (enExample)
SG (2) SG11201604787SA (enExample)
UA (1) UA121108C2 (enExample)
WO (1) WO2015089475A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10765629B2 (en) * 2017-07-25 2020-09-08 Allergan, Inc. Solid complex, preparations and uses thereof
US20230338194A1 (en) * 2020-01-29 2023-10-26 Kci Licensing, Inc. Mutliple fluid pathway connector with foam supports

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU645563A3 (ru) * 1972-07-13 1979-01-30 Пфайзер Инк (Фирма) Способ получени промежуточных соединений дл получени простагландинов
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6602900B2 (en) * 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
RU2217145C2 (ru) * 1997-11-19 2003-11-27 Аллерган Сэйлс, Инк. 2-гетероарилалкенилпроизводные циклопентангептан(ен)овой кислоты

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69613693T2 (de) * 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU645563A3 (ru) * 1972-07-13 1979-01-30 Пфайзер Инк (Фирма) Способ получени промежуточных соединений дл получени простагландинов
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6602900B2 (en) * 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
RU2217145C2 (ru) * 1997-11-19 2003-11-27 Аллерган Сэйлс, Инк. 2-гетероарилалкенилпроизводные циклопентангептан(ен)овой кислоты

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mino R. Caira, "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, Vol. 198, рр.163-208,1998, DOI: 10,1007/3-540-69178-2_5. *
Химический энциклопедический словарь под редакцией И.Л. Кнунянца, М. "Советская *
Химический энциклопедический словарь под редакцией И.Л. Кнунянца, М. "Советская Энциклопедия", 1983, с.130-131. *

Also Published As

Publication number Publication date
US9353079B2 (en) 2016-05-31
CN105814033A (zh) 2016-07-27
UA121108C2 (uk) 2020-04-10
CA2933556A1 (en) 2015-06-18
AU2014361794A1 (en) 2016-06-16
AU2014361794B2 (en) 2019-04-04
CN105814033B (zh) 2019-10-25
CL2016001448A1 (es) 2017-03-03
IL245917A0 (en) 2016-08-02
EP3080096A1 (en) 2016-10-19
SG11201604787SA (en) 2016-07-28
US20150166504A1 (en) 2015-06-18
IL283810A (en) 2021-07-29
BR112016013594A8 (pt) 2020-05-19
JP2016539994A (ja) 2016-12-22
US20170087163A1 (en) 2017-03-30
SA516371307B1 (ar) 2018-10-04
KR20160097310A (ko) 2016-08-17
BR112016013594A2 (enExample) 2017-08-08
IL245917B (en) 2021-06-30
SG10201709702UA (en) 2018-01-30
WO2015089475A1 (en) 2015-06-18
MX2016007717A (es) 2016-09-09
CL2019000471A1 (es) 2019-07-12
JP2020073513A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
JP2020073513A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
AU2020394597B2 (en) 1,2,4-oxadiazole derivatives as liver X receptor agonists
JP5550644B2 (ja) （１ｒ，２ｓ，３ｒ）−１−（２−（イソオキサゾール−３−イル）−１ｈ−イミダゾール−４−イル）ブタン−１，２，３，４−テトラオールの固体形態及びその使用方法
KR20230158458A (ko) 리피테그라스트 결정형 및 이를 포함하는 약제학적 조성물
ES2733756T3 (es) Agentes terapéuticos para el tratamiento de hipertensión ocular
TWI659041B (zh) 類固醇樣化合物之多晶型形式以及其製備方法及用途
HK1227389A1 (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
HK1227410A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
HK1227389B (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
JPH06102664B2 (ja) 局所的に有効なカルボニツクアンヒドラーゼ阻害剤としての５―カルバモイルチエノ〔２，３―ｂ〕チオフエン―２―スルホンアミド類及び製造方法
JPH11500754A (ja) 新規化合物および多発性硬化症の処置法
CN103764622A (zh) N,n-二烷基亚烷基酯、其组合物以及其使用方法
KR20240004600A (ko) (r)-옥시부티닌 d-말레이트의 고체 형태
WO2004058353A2 (en) Therapeutic use of selective noradrenaline reuptake inhibitors
HK1178524B (en) Therapeutic agents for treatment of ocular hypertension